While phlebotomy is a standard treatment for low-risk PV, it often results in fluctuating hematocrit levels. This creates an illusion of control, as levels may be on target immediately post-treatment but rise significantly between sessions, highlighting the need for more consistent therapies.
For young or hesitant low-risk PV patients, framing the initiation of cytoreductive therapy as a temporary trial, rather than a lifelong commitment, can ease anxiety. This approach allows patients and physicians to assess symptomatic benefits without the pressure of a permanent decision.
Interferon can take 6-8 months to achieve a complete hematologic response. To manage patients during this period and avoid frequent phlebotomies, clinicians can prescribe a short, overlapping course of faster-acting hydroxyurea, providing immediate control while transitioning to the long-term therapy.
Proactively, some hematologists now offer interferon-based therapy to very young, asymptomatic low-risk PV patients. The rationale is to leverage the drug's potential for disease modification by reducing JAK2 allele burden early on, even though this is not yet a formal guideline-supported indication.
Despite label recommendations for rapid dose escalation of ropeginterferon, experienced clinicians advocate for a slower, more patient-centric approach. This prioritizes long-term tolerability and adherence, which is crucial for achieving disease modification, over achieving rapid hematologic control.
Unlike in CML where treatment-free remission is an established goal, discontinuing interferon in PV after a deep molecular response is considered theoretical and experimental. Clinicians caution against setting this as an expectation for patients, as most will require indefinite therapy to maintain control.